Cell & Gene
Therapy CTDMO
Contract Testing, Development,
and Manufacturing Services for Advanced Therapies.
Subscribe to our newsletter
Delivering the Future
of Medicine
We are a global contract testing, development and manufacturing organization, (CTDMO). We enable the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies. Our services and solutions accelerate time to market and support customer programs around the world. Our vision is that one day, every drug can be made, and every disease can be treated.
Learn More About UsInnovative and Transformative Services
For more than 20 years, we have been working with pioneers in advanced therapies to help them successfully discover, develop, manufacture and release their products for patient use.
Our
Capabilities
Expertise
Facilities
Quality
Regulatory
Supply Chain
Modalities and Therapeutic Areas
Our experience and services cover CAR-T, T-Cell, TIL, MSC, AAV, Lenti, mAbs, Vaccines and other common advanced therapies.
Autologous
Allogeneic
Monoclonal Antibodies
Vaccines
Viral Vectors
Articles & Events

Advanced Therapies Acquired by Altaris
Philadelphia, U.S. and Oxford, U.K. sites and capabilities spun out of WuXi AppTec We are excited to share that Altaris completed its acquisition of Advanced Therapies U.S. and OXGENE (together “Advanced Therapies”) on 7 March 2025. Advanced Therapies is now fully owned by Altaris and headquartered in the United States. Altaris is an investment firm […]